

ARGANZ Meeting

8 – 9 March, 2025

Gold Coast Convention & Exhibition Centre

Saturday 8 March

0830-1030 SESSION 1: Opening Plenary

Welcome

0830-0840 Dr Jessica Yang

0840-0915 Imaging the bone marrow transplant patient (focus on GvHD)

Prof Christine "Cooky" Menias

0915-0945 Prostate cancer in the MRI era

Prof Clare Tempny

- To understand the Role of MRI in Prostate cancer from detection to staging
- Overview of PI-RADS and its results in clinical care
- To learn how MR can guide biopsy and therapy

0945-1015 The indeterminate small liver lesion: when and how to follow up

Prof Yves Menu

1015-1030 Panel Q&A

1030-1100 Morning Tea and Industry Exhibition

1100-1230 SESSION 2A: GIT

IgG4 in the abdomen

1100-1125 Dr Mark Goodwin

- To learn about the common and uncommon patterns of IgG4-related disease in the abdomen and pelvis.
- To learn tips and tricks for differentiating IgG4-related disease from other disease entities.

1125-1145 GI manifestations of vasculitis

Dr Katerina Mastrocostas

- Classification of vasculitides that affect the gastrointestinal tract and their presentation.
- Diagnostic pathway for vasculitis involving the gastrointestinal tract.
- Imaging manifestations of vasculitis involving the gastrointestinal tract.

1145-1205 Visceral artery dissection

Dr John Vedelago

1100-1230 SESSION 2B: Pelvis and Renal

MRI screening for hereditary renal tumors

1100-1120 Dr Sonja Gustafson

- Hereditary conditions that qualify for annual screening and the appearance of kidneys in those with these conditions & their potential lesion appearances at screening & diagnosis.

1120-1140 The sinking ship: MRI of the pelvic floor

Dr Arjuna Somasundaram

- Appreciate the utility of dynamic pelvic floor MRI.
- Learn what the referrer wants, and what the radiologist should look for.
- Understand the fundamentals of how to perform and report these studies.

1140-1220 Rectal cancer: Making a difference with MRI

Dr Kirsten Gormly

	<ul style="list-style-type: none"> - To recognise the imaging features of visceral artery dissection in the abdomen. - To understand the distribution and frequency of this pathology. - To incorporate a visceral artery review into our abdominal cross sectional imaging search pattern. 		<ul style="list-style-type: none"> - How to get the most from the latest imaging techniques - Staging updates - Can the patient avoid surgery after treatment?
1205-1220	Cystic lesions of the abdomen Dr Arani Halder	1220-1230	Panel Q&A
	<ul style="list-style-type: none"> - Become familiar with common and rare cystic lesions in the abdomen and pelvis. - Understand the differential diagnosis, initial management and follow up of these lesions. 		
1220-1230	Panel Q&A		
1230-1330	Lunch and Industry Exhibition		
1330-1500	SESSION 3A: Hepatobiliary	1330-1500	SESSION 3B: Female Pelvis
1330-1400	Biliary tumours: Making challenging cases easy Prof Yves Menu	1330-1350	Endometriosis - The modern curse A/Prof Anusch Yazdani
			<ul style="list-style-type: none"> - To describe the common clinical presentations of endometriosis. - To describe the classification and staging systems of endometriosis - To describe management options for those diagnosed with endometriosis in line with the Australian Clinical Management Guidelines.
1400-1420	Hépatites sans frontières: the global liver infection quiz Dr James Seow	1350-1410	MRI for endometriosis in the pre-surgical patient Dr Bridget Sutton
	<ul style="list-style-type: none"> - To interactively test your infectious liver disease imaging skills and general geography knowledge 		<ul style="list-style-type: none"> - Scan protocol optimization and systematic reporting. - Presurgical mapping of DIE in anterior, middle and posterior compartments of pelvis. - MRI diagnosis and preoperative assessment of suspected extra pelvic disease eg. diaphragm, anterior abdominal wall, sacral plexus or sciatic nerve.
1420-1435	Liver ultrasound elastography and fat quantification Dr Paul Simkin	1410-1450	How to approach the female pelvic MRI Prof Christine "Cooky" Menias
	<ul style="list-style-type: none"> - The principles of acquiring reliable liver stiffness measurements with US based shear wave elastography, including quality assurance and troubleshooting. - Dealing elastography results that are discordant with the B-mode imaging. - A brief overview of ultrasound fat quantification technology. 		
1435-1450	What's new in HCC surveillance and assessment of treatment response Dr Jessica Yang		
	<ul style="list-style-type: none"> - Find out what's new in HCC surveillance - Find out what's new in the assessment of HCC treatment response - Find out about new LI-RADS updates 		
1450-1500	Panel Q&A	1450-1500	Panel Q&A
1500-1530	Afternoon Tea and Industry Exhibition		
1530-1700	SESSION 4A: Oncology	1530-1700	SESSION 4B: Prostate and Bladder Cancer
1530-1600	Neuroendocrine tumours: Why the radiologist needs to think differently Prof Yves Menu	1530-1600	Prostate MR: The technical stuff including quality assessment Prof Clare Tempany
			<ul style="list-style-type: none"> - To understand the technical aspects of the 3 key sequences required for PI-RADS v2.1 - To learn how to apply a quality review-PI-QUAL - To learn the MRI appearances of benign conditions of the prostate

- 1600-1615 DOTATATE-PET for General and GI Radiologists**
 Dr Tom Huang
- Recognise the physiologic distribution of DOTATATE-PET and common incidentals.
 - Krenning score and common diagnostic pitfalls.
 - Basics of Lutetium Theranostics and interpreting post-treatment scans.
- 1615-1630 Tips on cancer staging**
 Dr Divya Mehta
- Discuss imaging appearances of a few primary abdominal malignancies, review their TNM staging and patterns of spread.
- 1630-1645 RECIST reporting in a nutshell**
 Dr Sally Ayesa
- Revise the RECIST 1.1 criteria for reporting oncology studies.
 - Consider how RECIST 1.1 reporting criteria can be used in practice with case examples.
- 1645-1700 Panel Q&A

- 1600-1620 Bladder cancer assessment (VI-RADS) and the utility of PET**
 Dr Jash Agraval
- 1620-1650 Prostate recurrence reporting and role of MRI in post-focal therapy assessment**
 Prof Clare Tempany
- To understand current Prostate cancer treatments used for loco-regional disease.
 - To review the appearance of the prostate gland after therapy
 - To learn how to identify and report post treatment local recurrence
- 1650-1700 Panel Q&A

1700-1745 Welcome Function and Industry Exhibition

1900-2300 Meeting Dinner - Isoletto Privé, Level 6, The Star Gold Coast

Sunday 9 March

0830-1030 SESSION 5

0830-0900 **Liver metastases: New trends that are useful in daily practice**

Prof Yves Menu

0900-0930 **CT internal hernias and internal hernias in gastric bypass surgery patients**

Prof Christine "Cooky" Menias

0930-1000 **Research discussion and tips to have your article published**

Prof Cooky Menias (Editor in Chief - Radiographics), Prof Yves Menu (Immediate Past Editor in Chief - European Radiology), Dr Gabes Lau (Editor in Chief - JMIRO)

1000-1030 **Mendelson Research Prize Presentations**

1000-1010 Prognosticating factors in PET CT and MRI of cervical cancer treated with chemoradiotherapy

Dr Dominic Ku

1010-1020 External validation of a deep learning model for automated lesion detection and bony metastasis classification on PSMA PET-CT in prostate cancer

Dr Minh-Son To

1020-1030 Double-oblique axial T2 imaging during rectal MRI – A case series

Dr Peter Zarzour

1030-1100 **Morning Tea and Industry Exhibition**

1100-1300 **SESSION 6: Renal MDT**

1100-1115 **Urologist's approach to renal lesions/incidentalomas**

Dr Chris Tracey (Urologist)

- Appreciate the approach to small renal mass from a urologist's perspective.
- Appreciate the nuances of imaging important for perioperative planning with respect to partial nephrectomy.

1115-1125 **SBRT for renal cell cancer**

Dr Andrew Oar (Radiation Oncologist)

1125-1135 **Percutaneous ablation for renal cell cancer**

Dr John Grieve (Interventional Radiologist)

1135-1150 **Renal contrast enhanced ultrasound - Breaking out of the bubble**

Dr Dean Rabinowitz

- Review the basics of contrast enhanced ultrasound as a technique.
- Review the current approach to diagnosis of cystic and solid renal lesions
- Consider the specific indications where CEUS should be used as an alternative or adjunct to other methods.
- Observe key examples of cystic and solid lesions using CEUS technique.

1150-1300 **MDT - Renal**

Dr Arj Somasundaram (Radiologist), Dr John Grieve (Interventional Radiologist), Dr Andrew Oar (Radiation Oncologist), Dr Chris Tracey (Urologist), Dr Admire Matsika (Pathologist)

- Learn the nuances of RCC management through robust debate and discussion.
- Tips and tricks for imaging RCCs and how to provide added MDT value.
- A showcase of multidisciplinary specialist knowledge.

1300-1315 **ARGANZ Annual General Meeting**

1300-1400 **Lunch and Industry Exhibition**

1400-1600 **SESSION 7**

1400-1405	Mendelson Research Prize / ARGANZ Research & Education Grant Announcements Dr Won Kyung Sung
1405-1445	Cases from the Cooky Jar Prof Christine "Cooky" Menias
1445-1505	Improving radiology reporting globally and locally: Who, how and why? (And it's not AI) Dr Kirsten Gormly
1505-1515	Article review - Pancreatic IPMN Kyoto protocol Dr Geertje Noe - Briefly outline of the Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas and its latest revision. - To become familiar with the latest management algorithm for intraductal papillary mucinous neoplasm.
1515-1525	Myth buster #1 - Sorry, this can't be biopsied A/Prof Tom Sutherland - Discuss the breadth of lesions that can be biopsied. - Discuss the importance of biopsy to guide management and support minimally invasive therapies. - Discuss which vessels just don't bleed. - How to evaluate the risk of a radiologist with a needle versus a surgeon with a knife.
1525-1535	Myth buster #2 - This dilated CBD is a choledochal cyst Dr Mayooraan Kandasamy - A brief overview of the imaging features, morphology and classification of choledochal cysts. - Learn about differentiating extrahepatic choledochal cysts from a dilated CBD.
1535-1545	Myth buster #3 - You can't give gad in renal failure Dr Matthew Aitken - Understand the safety profile of gadolinium-based contrast agents (GBCAs) and their use in patients with renal failure. - Differentiate between high-risk and low-risk GBCAs and their implications for nephrogenic systemic fibrosis (NSF). - Apply current guidelines to safely administer GBCAs in patients with impaired renal function.
1545-1555	Panel Q&A
1555-1600	Closing remarks Dr Jessica Yang